Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer
Daniel P Salem,Laura T Bortolin,Dan Gusenleitner,Jonian Grosha,Ibukunoluwapo O Zabroski,Kelly M Biette,Sanchari Banerjee,Christopher R Sedlak,Delaney M Byrne,Bilal F Hamzeh,MacKenzie S King,Lauren T Cuoco,Timothy Santos-Heiman,Gabrielle N Barcaskey,Katherine S Yang,Peter A Duff,Emily S Winn-Deen,Toumy Guettouche,Dawn R Mattoon,Eric K Huang,Randy W Schekman,Anthony D Couvillon,Joseph C Sedlak
DOI: https://doi.org/10.1016/j.jmoldx.2024.08.006
2024-09-24
Abstract:Detection of cancer early, when it is most treatable, remains a significant challenge because of the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. Detection of their presence is made more difficult by a lack of abundant tumor-specific indicators (ie, protein biomarkers, circulating tumor DNA) that would enable detection using a noninvasive diagnostic assay. To overcome these obstacles, we have developed a liquid biopsy assay that interrogates circulating extracellular vesicles (EVs) to detect tumor-specific biomarkers colocalized on the surface of individual EVs. We demonstrate the technical feasibility of this approach in human cancer cell line-derived EVs, where we show strong correlations between assay signal and cell line gene/protein expression for the ovarian cancer-associated biomarkers bone marrow stromal antigen-2, folate receptor-α, and mucin-1. Furthermore, we demonstrate that detecting distinct colocalized biomarkers on the surface of EVs significantly improves discrimination performance relative to single biomarker measurements. Using this approach, we observe promising discrimination of high-grade serous ovarian cancer versus benign ovarian masses and healthy women in a proof-of-concept clinical study.